Cuba’s biotech industry expands through decades of innovation, overseas exploration

Posted on Posted in Sin categoría

HAVANA, June 24 (Xinhua) — Cuba’s half a billion-dollar biotechnological industry, considered key to the country’s future, is looking to expand with innovation and overseas market development. “Today we export our established products to about 50 countries, and we have a portfolio of innovative and unique drugs that are in different stages of research or clinical trials,” Merardo Pujol, business development director at Cuba’s Center for Genetic Engineering and Biotechnology (CIGB), told Xinhua. Cuban scientists are looking to the future for new ways to create unique and innovative drugs that not only benefit the island’s population but also millions of […]

Heberprot-p, Reaches Slovakia, First Stop in the European Union

Posted on Posted in Sin categoría

Havana, May 24.- A delegation of Cuban doctors arrived in Slovakia to bring advisory in the application of Heberprot-p, the only drug in the world for the treatment of diabetic foot, reported today CubaMinrex foreign Ministry’s website. The note highlighted that Slovakia will be the first country of the European Union where the injection, made by the Center of Genetic Engineering and Biotechnology has been in the market for almost a decade. Data from the National Center for Medical Information also specify that more than 8,000 people suffer from this disease in the European nation. The director of the Health […]

New treatment for diabetic foot ulcers launched in Kuwait

Posted on Posted in Sin categoría

The Heberprot-P, a developed treatment for diabetic foot ulcers, recently registered in Kuwait, was launched by the Center for Genetic Engineering and Biotechnology (CIGB) in coordination with Kuwait’s Central Gulf Medical Company (CGMC) at the Hotel Mövenpick on 6 March. The launch ceremony was attended by Dr. Eulogio Pimentel Vázquez, General Director of CIGB, who outlined the development of Cuba in the field of biotechnology, and detailed the products that have contributed to the diagnosis, prevention and treatment of many diseases, and their impact on health, agriculture and the environment. Dr. Jorge Berlanga, creator of Heberprot P and Dr. José […]

Heberprot-P registered in 23 countries

Posted on Posted in news

Ten years after receiving its health registration and approval to be used in the national health system, the medicine Heber¬prot-P has been used to treat over 55,000 Cuban patients nationwide, with positive results Developed by a team of experts led by Dr. Jorge Berlanga Acosta from the Center for Genetic Engineering and Biotechnology (CIGB), Heber­prot-P is an injectable medication used to treat advanced foot ulcers in diabetic patients by accelerating the healing process, thus reducing the risk of amputation in over 78% of cases. The only one of its kind in the world, the product received the Gold Medal awarded […]

Type 11 diabetes cases expected to rise by 200mn globally over next two decades

Posted on Posted in news

Diabetes is the catastrophe of the 21st century, remarked Sir Michael Hirst, the visiting President of the International Diabetes Federation (IDF) headquartered in Brussels, Belgium. This debilitating disease is a challenge to the world, to Sri Lanka and to every other country, he underscored. “No longer are those afflicted old people, even many teenagers are now diabetic”. With a surge in Type 11 diabetes, the number is expected to rise by 200 million globally over the next 20 years, Sir Michael said in an interview with The Sunday Island on the sidelines of the recent launch of Heberprot-P, an innovative […]